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Statement of Need 
Lung cancer is the leading cause of cancer death in the United States and accounted for an 
estimated 161,840 deaths in 2008. Despite several decades of extensive research, the 
median survival for patients with non-small cell lung cancer (NSCLC) is approximately 1 
year. Seventy percent of patients diagnosed with NSCLC have locally advanced or 
metastatic disease. Although multiple studies have confirmed the efficacy of platinum doublets 
for the treatment of advanced or metastatic NSCLC, a plateau in treatment efficacy seems to 
have been reached. In an effort to increase efficacy and reduce treatment-related toxicities, 
investigators have focused on developing strategies that involve molecular considerations for 
patient selection in the early and advanced stage treatment settings. The identification of 
biomarkers that predict response to chemotherapy and targeted therapy has the potential to 
transform the treatment paradigm of NSCLC from one that relies on clinical characteristics,
such as tumor stage, performance status, and smoking history, to one where the analysis of
molecular characteristics of individual patients is used for therapeutic decision making. At the 
end of this activity, participants will be able to evaluate data from recent clinical trials that are 
investigating molecular biomarkers as potential predictors of response or resistance to 
chemotherapeutic and targeted therapies for patients with NSCLC.
Target Audience 
This activity is intended for medical oncologists, thoracic surgeons, nurses, pharmacists, 
physician assistants, and other healthcare professionals interested in the treatment of 
patients with NSCLC.    
Educational Objectives 
On completion of this activity, participants will be able to: 
1. Describe the rationale for using molecular markers to individualize treatment for patients
    with NSCLC.
2. Evaluate the use of molecular profiling to predict clinical outcomes in the adjuvant setting
    for patients with NSCLC.
3. Discuss the use of predictive markers to direct selection of chemotherapeutic agents for
    the treatment of NSCLC.
4. Discuss the use of molecular markers to refine the use of targeted agents for the
    treatment of NSCLC.
5. Describe data supporting the use of clinical prognostic and predictive factors for patients
    with NSCLC receiving targeted therapies.
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Method of Participation 
Successful completion of this continuing education activity includes reviewing the target 
audience, educational objectives, and author disclosures, as well as reading the course 
materials in their entirety. 
Accreditation
Physicians : The Center for Biomedical Continuing Education (CBCE™) is accredited by 
the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing 
medical education for physicians.
The CBCE designates this educational activity for a maximum of 1.25 AMA PRA Category 1 
Credits™. Physicians should only claim credit commensurate with the extent of their 
participation in this activity.  
Physician Assistants: AAPA accepts certificates of participation for educational activities 
certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA 
Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical 
society. Physician assistants may receive a maximum of 1.25 hours of Category 1 credit for 
completing this program.
Nurses: The CBCE™ is accredited as a provider of continuing nursing education by the 
American Nurses Credentialing Center’s Commission on Accreditation.
The CBCE designates this educational activity for 1.25 contact hours.
Accreditation by the American Nurses Credentialing Center’s Commission on Accreditation 
refers to recognition of educational activities and does not imply approval or endorsement of 
any product. 
Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is 
accredited by the Accreditation Council for Pharmacy Education (ACPE) as a 
provider of continuing pharmacy education. 
CPE Credit: 1.25 contact hours or 0.125 CEUs
Universal Program Number: 195-000-09-016-H01-P 
Credit Instructions 
Successful completion of this activity requires the following: 
• Read the journal supplement. 
• Score 70% or above on the posttest. 
• Complete the Evaluation and Request for Credit Form. 
• Submit the completed posttest and form to the CBCE following the activity to receive 
credit.
Certificate
Participants will receive their certificate 4-6 weeks after the CBCE receives their posttest 
and form. 
Acknowledgement of Commercial Support 
The CBCE gratefully acknowledges the educational grants provided by Genentech 
BioOncology/OSI Pharmaceuticals, Inc.; Lilly USA, LLC; Pfizer Oncology; and sanofi-aventis.
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Educational Inquiries 
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, 
TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.
Disclaimer
The content and views presented in this educational activity are those of the faculty and do 
not necessarily reflect the opinions or recommendations of the CBCE, Genentech 
BioOncology/OSI Pharmaceuticals, Inc.; Lilly USA, LLC; Pfizer Oncology; or sanofi-aventis.
This material has been prepared based on a review of multiple sources of information but is 
not comprehensive. Participants are advised to critically appraise the information presented, 
and they are encouraged to consult the available literature on any product or device 
mentioned in this program.
Disclosure of Unlabeled Uses 
This educational activity may contain discussion of published and/or investigational uses of 
agents that are not approved by the US Food and Drug Administration. For additional 
information about approved uses, including approved indications, contraindications, and 
warnings, please refer to the prescribing information for each product or consult the latest 
edition of the Physicians’ Desk Reference.
Disclosure of Financial Relationships With Any Commercial Interest
As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone 
who is in a position to control the content of an educational activity discloses all relevant 
financial relationships with any commercial interest, and identifies and resolves all conflicts 
of interest before the educational activity. The CBCE defines “relevant financial relationships” 
as any amount occurring within the past 12 months.
Financial relationships are those relationships in which the individual benefits by receiving a 
salary, royalty, intellectual property rights, consulting fee, honorarium, ownership interest (eg, 
stocks, stock options, or other ownership interest, excluding diversified mutual funds), or 
other financial benefit. Financial benefits are usually associated with roles such as 
employment, management, independent contractor (including contracted research), 
consulting, speaking and teaching, membership on advisory committees or review panels, 
board membership, and other activities for which remuneration is received or expected. The 
CBCE considers relationships of the person involved in the educational activity to include 
financial relationships of a spouse or partner. 
Faculty who refuse to disclose relevant financial relationships will be disqualified from being 
a planning committee member, a teacher, or an author, and cannot have control of or 
responsibility for the development, management, presentation, or evaluation of the 
educational activity. For an individual with no relevant financial relationship, participants must 
be informed that no relevant financial relationship exists.
Disclosure of Potential Conflicts of Interest 
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE 
activities. The identified conflicts of interest are thoroughly evaluated for fair balance, scientific 
objectivity relative to studies utilized in this activity, and patient-care recommendations. The 
CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art 
education.
The following faculty reported real or apparent conflicts of interest, and these 
conflicts have been resolved through a peer-review process:
Rogerio Lilenbaum, MD
Consultant     
AstraZeneca Pharmaceuticals LP   
Genentech, Inc. 
Lilly USA, LLC 
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Consultant
ImCone Systems Incorporated 
Lilly USA, LLC 
Honoraria
Lilly USA, LLC 
Antoinette Wozniak, MD 
Advisory Board 
AstraZeneca Pharmaceuticals LP 
Bristol-Myers Squibb Company 
Genentech, Inc.
Lilly USA, LLC 
Consultant
AstraZeneca Pharmaceuticals LP 
Bristol-Myers Squibb Company 
Genentech, Inc.
Lilly USA, LLC 
Grant/Research Support 
Lilly USA, LLC 
Honoraria
Genentech, Inc.
Lilly USA, LLC 
Speaker’s Bureau 
Genentech, Inc.
Lilly USA, LLC
The following faculty declared they have no financial relationships that require 
disclosure:
Lecia Sequist, MD, MPH 
David Harpole, MD
Institutional Disclosure 
The CBCE receives educational grants from the pharmaceutical industry and other 
commercial sources. Companies providing grants to the CBCE include the commercial 
supporters of this activity as well as the manufacturers of certain drugs and/or devices 
discussed in this activity. 
Staff Disclosures 
The CBCE staff have declared they have no financial relationships that require disclosure. 
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